 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| VAX-24 / Vaxcyte
Enrollment closed: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants (clinicaltrials.gov) - Mar 12, 2024
P2, N=802, Active, not recruiting, Sponsor: Vaxcyte, Inc.
Recruiting --> Active, not recruiting
- || VAX-24 / Vaxcyte
P1/2 data, Clinical Trial,Phase II, Journal: Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial. (Pubmed Central) - Feb 26, 2024
P1/2
Recruiting --> Active, not recruiting VAX-24 had a safety profile similar to PCV20 at all doses, with the 2
- Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer, VAX-24 / Vaxcyte
CELL FREE PROTEIN SYNTHESIS PLATFORM TO EXPAND PNEUMOCOCCAL SEROTYPE COVERAGE AND INCREASE IMMUNE RESPONSE (Ballroom West) - Jan 4, 2024 - Abstract #ISPPD2024ISPPD_38;
VAX-24 had a safety profile similar to PCV20 at all doses, with the 2 Methods Clinical data include a total of 1042 pneumococcal vaccine na
- ||||| VAX-24 / Vaxcyte
New P2 trial: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants (clinicaltrials.gov) - May 6, 2023
P2, N=800, Recruiting, Sponsor: Vaxcyte, Inc.
- |||| VAX-24 / Vaxcyte
Trial completion, Trial completion date, Trial primary completion date: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults (clinicaltrials.gov) - Apr 21, 2023
P2, N=207, Completed, Sponsor: Vaxcyte, Inc.
Methods Clinical data include a total of 1042 pneumococcal vaccine na Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
- |||| VAX-24 / Vaxcyte
Trial completion: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults (clinicaltrials.gov) - Mar 30, 2023
P1/2, N=771, Completed, Sponsor: Vaxcyte, Inc.
Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023 Active, not recruiting --> Completed
- || VAX-24 / Vaxcyte
Monic Gandhi is pro-COVID vax 24/7. (Twitter) - Sep 23, 2022
- ||| VAX-24 / Vaxcyte
Enrollment closed: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults (clinicaltrials.gov) - Sep 14, 2022
P2, N=207, Active, not recruiting, Sponsor: Vaxcyte, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| VAX-24 / Vaxcyte
Enrollment open: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults (clinicaltrials.gov) - Jul 28, 2022
P2, N=200, Recruiting, Sponsor: Vaxcyte, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| VAX-24 / Vaxcyte
Enrollment closed: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults (clinicaltrials.gov) - Jul 27, 2022
P1/2, N=864, Active, not recruiting, Sponsor: Vaxcyte, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| VAX-24 / Vaxcyte
New P2 trial: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults (clinicaltrials.gov) - Mar 27, 2022
P2, N=200, Not yet recruiting, Sponsor: Vaxcyte, Inc.
- | VAX-24 / Vaxcyte
New P1/2 trial: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults (clinicaltrials.gov) - Mar 4, 2022
P1/2, N=864, Recruiting, Sponsor: Vaxcyte, Inc.